Apart from clinically proven efficacy of the FcRn-inhibitor efgartigimod for treatment of CIDP [3], which has been recently approved for this indication, complement inhibitory therapies are under investigation. Here, FCGRT is linked to chronic inflammatory demyelinating polyradiculoneuropathy.